Tag: Dexcom
Study: Dexcom G7 improves A1C in Type 2 diabetes
October 21, 2026HME News Staff
SAN DIEGO – Dexcom G7 users experienced an average 1.6% A1C reduction from a mean baseline of 8.8%, a 0.9% greater reduction compared with routine care, according to the results from the CONNECT randomized controlled trial published The New England Journal of Medicine. Dexcom G7 users also spent approximately five additional hours per day in the glucose target range of 70–180 mg/dL compared with those receiving routine care. “Publication of CONNECT in The New England Journal of...
Dexcom reports on access, attitudes to diabetes technology
September 29, 2026HME News Staff
MILAN – A majority of health care providers (HCPs) recognize continuous glucose monitoring (CGM) as essential to Type 2 diabetes management, according to a new report published by Dexcom ahead of the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan Sept. 28-Oct. 2.
Eighty-nine percent of HCPs believe CGM helps them assess treatment adherence between appointments, and more than half of current CGM users report they have followed their treatment plan...
In brief: Accendra Health CEO, Reliable Medical buy, SpinLife franchise
September 18, 2026HME News Staff
RICHMOND, Va. – Accendra Health has named Kenneth Gardner-Smith as its next president and CEO, succeeding Edward Pesicka, who announced his plans to retire in August.
Gardner-Smith, who has served on the company’s board of directors since March 2022, is expected to assume the role early in the fourth quarter of 2026. He currently serves as CEO of Veritas Veterinary Partners, a national specialty and emergency veterinary platform, where he spearheaded a strategy reset and executive...
Dexcom promotes Sylvain to COO-CFO
September 17, 2026HME News Staff
SAN DIEGO – Dexcom has promoted Jereme Sylvain to COO, in addition to his duties as CFO. In this expanded role, he will assume oversight of Dexcom’s global operations and quality teams, driving greater alignment, speed and accountability across the company as it executes on its vision for growth and commitment to operational excellence. “Jereme is an exceptional leader and a valued strategic partner across Dexcom,” said Jake Leach, president and CEO. “His deep understanding...
Dexcom adds Glenn Boehnlein, former Stryker exec, to board of directors
September 15, 2026HME News Staff
SAN DIEGO – Dexcom has appointed Glenn Boehnlein, a health care exec and finance leader with more than 20 years of experience in the med-tech industry, to its board of directors. He served as vice president and CFO of Stryker Corp. from 2016-25, helping to guide the organization through a period of significant growth, innovation and global expansion. “Earlier this summer, we launched a search for a new independent director with deep med-tech experience and a proven track record of global...
FDA selects Dexcom for digital health pilot
July 29, 2026HME News Staff
WASHINGTON – The U.S. Food and Drug Administration (FDA) has selected Dexcom as the first participant in its Technology-Enabled Meaningful Patient Outcomes for Digital Health Devices Pilot, or TEMPO. The pilot, conducted in partnership with the CMS Innovation Center, is designed to evaluate how digital health technologies perform in real-world settings while expanding access to technology-enabled care for people with Medicare. The program is intended to help patients participating in CMS’s...
Dexcom G7 15 Day receives Health Canada authorization
July 15, 2026HME News Staff
BURNABY, British Columbia – Health Canada has authorized the Dexcom G7 15 Day Continuous Glucose Monitoring System for adults with diabetes. The system provides real-time glucose readings for up to 15.5 days, including a 12-hour grace period for replacing a finished sensor. Dexcom says the extended wear time will reduce the number of monthly sensor changes and the amount of related waste. “Small improvements can make a meaningful difference for people living with diabetes,” said...
FDA gives greenlight to Dexcom OTC CGM
June 16, 2026HME News Staff
WASHINGTON – The U.S. Food and Drug Administration (FDA) has cleared for marketing the first over-the-counter (OTC) continuous glucose monitor (CGM) for children: Dexcom’s Stelo Glucose Biosensor System, an integrated CGM (iCGM) indicated for people two years of age and older who do not use insulin. The FDA previously cleared the Stelo Glucose Biosensor System OTC for individuals 18 years and older in March 2024. “Children deserve access to the best tools available to manage their...
In brief: Latest UHC-Synapse deal, Dexcom stolen sensors, WeOxy debut
May 29, 2026HME News Staff
SKOKIE, Ill. – UnitedHealthcare has announced that Synapse Health will manage durable medical equipment (DME) orders for certain UnitedHealthcare Medicare Advantage plans in additional states beginning Sept. 1, 2026.
For individual HMO & PPO plans, Synapse Health will manage DME for members in Connecticut, District of Columbia, Delaware, Maine, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania and Rhode Island.
For chronic special needs plans (C-SNP), Synapse...
Dexcom warns of stolen sensors meant to be discarded
May 27, 2026HME News Staff
SAN DIEGO – Dexcom says certain lots of Dexcom G7 sensors originally designated as scrap and intended for destruction were stolen during the destruction process, then sold by third parties.
Company identifies affected lots
At this time, Dexcom has identified two lots of Dexcom G7 sensors (1725204004 and 1725069002) that were stolen, sold and used by some customers.
“Nothing matters more to Dexcom than the safety of our users and maintaining the trust of the diabetes community,”...